ArticleVaccines2025
Norovirus in Pediatric Gastroenteritis: A Study in Argentine Hospitals Before and After the Introduction of Universal Rotavirus Vaccination.
Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Detection of Viruses of Public Health Importance in Wastewater Samples Using Conventional PCR Techniques and a Targeted Enrichment Whole Genome Sequencing Panel.Food and environmental virology · 2026Article
- Clinical characteristics associated with gastrointestinal bleeding in neonates with laboratory-confirmed norovirus gastroenteritis.Frontiers in public health · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Norovirus (NoV) is a leading cause of acute gastroenteritis (AGE) in young children worldwide. Following the introduction of universal rotavirus (RVA) vaccination in Argentina in 2015, the role of NoV in pediatric AGE warrants evaluation. This study aimed to assess the prevalence, clinical characteristics, and molecular diversity of NoV in children under five years of age, comparing the periods before and after RVA vaccine implementation.
methodsA descriptive observational study was conducted in two pediatric hospitals in Argentina. Stool samples were obtained from both outpatient and hospitalized children presenting with acute gastroenteritis (AGE) during two distinct one-year periods: 285 samples from the pre-vaccination period (2011-2012) and 212 samples from the post-vaccination period (2019-2020). NoV, RVA and other viral enteropathogens were detected by RT-qPCR or immunoassay. Positive NoV samples were genotyped by Sanger sequencing of the ORF1/ORF2 junction.
resultsNoV was detected in 30.1% (86/285) and 23.5% (50/212) of cases in the pre- and post-vaccination periods, respectively. Children under two years of age and inpatients had significantly higher NoV detection in both periods. NoV mono-infections were more frequent in post-vaccination period (72% vs. 50%). NoV GII predominated in both periods, with increased genotype diversity observed post-vaccination, including GII.3[P12], GII.4 Sydney[P16], GII.6[P7], and GII.2[P16].
conclusionsNoV remains a major cause of pediatric AGE in Argentina, particularly in children under two years old. Although NoV prevalence did not increase after RVA vaccine introduction, its clinical relevance persists. Continued molecular surveillance is essential to monitor genotype dynamics and implement prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.